Literature DB >> 23108527

Treatment of recurrent anterior uveitis with infliximab in patient with ankylosing spondylitis.

Junko Matsuda1, Toshikatsu Kaburaki, Shigeto Kobayashi, Jiro Numaga.   

Abstract

BACKGROUND: We describe a HLA-B27-positive Japanese man with recurrent severe anterior uveitis OU and ankylosing spondylitis (AS) who was successfully treated with infliximab. CASE: A 25-year-old HLA-B27-positive Japanese man presented with recurrent anterior uveitis OU. The symptoms were consistent with typical HLA-B27-associated uveitis, whereas the subsequent course, which consisted of frequent episodes of recurrent severe anterior uveitis, was atypical. Although the patient was treated with intensive topical corticosteroids, cycloplegic treatment, sub-Tenon triamcinolone acetonide injections, systemic corticosteroids and immunosuppressive agents, recurrence of the anterior uveitis persisted. Over 8 years there were 14 documented episodes of recurrent anterior uveitis OD and 10 OSs. At age 33, the patient was diagnosed with AS after a radiographic examination. We began infusions of infliximab (2.5 mg/kg) at 0, 2 and 6 weeks, and then every 8 weeks thereafter. The recurrent uveitis disappeared, and the immunosuppressive agents and oral corticosteroids were tapered and discontinued without relapse. All drugs other than infliximab were successfully stopped in October 2010. During the follow-up period, there were no adverse events.
CONCLUSION: A case of severe recurrent anterior uveitis OU in a patient with AS with infliximab was successfully treated. This is the first report describing the efficacy of infliximab in AS-associated uveitis in Japan.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23108527     DOI: 10.1007/s10384-012-0202-z

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  16 in total

1.  Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis.

Authors:  J M Benitez-Del-Castillo; J Garcia-Sanchez; T Iradier; A Bañares
Journal:  Eye (Lond)       Date:  2000-06       Impact factor: 3.775

2.  Clinical features and course of ankylosing spondylitis; as seen in a follow-up of 222 hospital referred cases.

Authors:  M WILKINSON; E G BYWATERS
Journal:  Ann Rheum Dis       Date:  1958-06       Impact factor: 19.103

3.  Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab.

Authors:  J Brandt; H Haibel; D Cornely; W Golder; J Gonzalez; J Reddig; W Thriene; J Sieper; J Braun
Journal:  Arthritis Rheum       Date:  2000-06

4.  Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.

Authors:  S van der Linden; H A Valkenburg; A Cats
Journal:  Arthritis Rheum       Date:  1984-04

5.  Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.

Authors:  Anat Galor; Victor L Perez; Jeffrey P Hammel; Careen Y Lowder
Journal:  Ophthalmology       Date:  2006-09-25       Impact factor: 12.079

6.  Infliximab-induced demyelination causes visual disturbance mistaken for recurrence of HLA-B27-related uveitis.

Authors:  Marina Papadia; Carl Peter Herbort
Journal:  Ocul Immunol Inflamm       Date:  2010-08-25       Impact factor: 3.070

Review 7.  Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept.

Authors:  J Braun; X Baraliakos; J Listing; J Sieper
Journal:  Arthritis Rheum       Date:  2005-08

8.  Infliximab in the treatment of refractory posterior uveitis.

Authors:  Annie Joseph; Dev Raj; Harminder S Dua; Pauline T Powell; Peter C Lanyon; Richard J Powell
Journal:  Ophthalmology       Date:  2003-07       Impact factor: 12.079

9.  Outcomes of HLA-B27-positive and HLA-B27-negative acute anterior uveitis.

Authors:  A Linssen; C Meenken
Journal:  Am J Ophthalmol       Date:  1995-09       Impact factor: 5.258

10.  Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study.

Authors:  M Rudwaleit; E Rødevand; P Holck; J Vanhoof; M Kron; S Kary; H Kupper
Journal:  Ann Rheum Dis       Date:  2008-07-28       Impact factor: 19.103

View more
  2 in total

Review 1.  The Use of Biologic Therapies in Uveitis.

Authors:  Sergio Schwartzman; Monica Schwartzman
Journal:  Clin Rev Allergy Immunol       Date:  2015-12       Impact factor: 8.667

2.  Efficacy and Safety of Infliximab in HLA-B27-associated Ocular Inflammation Refractory or Intolerant to Conventional Immunomodulatory Therapy.

Authors:  Asima Bajwa; Arash Maleki; Abhishek R Payal; Adriana Fandiño; María Inés Menéndez Padrón; Marisa Walsh; C Stephen Foster
Journal:  J Ophthalmic Vis Res       Date:  2020-10-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.